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A B S T R A C T
Background: Schizophrenia is one of the most disabling psychiatric syndromes with the prevalence of 1% in the
general population. Despite availability of various antipsychotics, negative symptoms and cognitive impairment
are diﬃcult to treat. In addition antipsychotic monotherapy is not eﬀective in most of these patients. Current
evidence indicates the roles of glutamatergic system in this disorder. N-acetyl cysteine (NAC) also increases
extracellular glutamate. This study was conducted to evaluate the clinical eﬀects of oral NAC as an add-on to
maintenance medication for the treatment of chronic schizophrenia.
Materials and methods: This 12-week, double-blind, randomized, placebo-controlled, clinical trial was performed
to determine the eﬀectiveness of 1200 mg N-acetyl cysteine as an adjunctive treatment with conventional an-
tipsychotic medications in 84 patients with chronic schizophrenia. The subjects were evaluated with the Positive
and Negative Syndrome Scale (PANSS), Mini-Mental State Examination (MMSE), and a standard neuropsycho-
logical screening test. Data were analyzed with SPSS-16 software.
Results: NAC-treated patients showed signiﬁcantly improvement in the positive (F = 5.47, P = 0.02) and ne-
gative (F = 0.20, df = 1) PANSS subscale. Also the general and total PANSS score of NAC group declined over
times whilst it was increased for placebo group. Regarding cognitive functions, improvement was observed in
some explored areas, such as attention, short-term and working memory, executive functioning and speed of
processing. There was no signiﬁcant diﬀerence between the 2 groups in the frequency of adverse eﬀects.
Conclusion: The present study detected improvement in positive, negative, general and total psychopathology
symptoms as well as cognitive performance with NAC treatment. It is also well-tolerated, safe and easy-to-use
agent as an eﬀective therapeutic strategy to improve outcome in schizophrenia treatment.
1. Introduction
Schizophrenia is one of the most disabling psychiatric syndromes with
the prevalence of 1% in the general population, the pathophysiology and
etiology of this disorder has remained unknown (Sadock et al., 2009;
Seeman, 2007; Sadock and Sadock, 2007). Schizophrenia increases the
morbidity and mortality risk and health care costs (Wu et al., 2005). One
of the considered mechanisms in etiology of schizophrenia is the defect in
antioxidant system that causes rise of lipid peroxides level. Oxidative stress
causes membrane defects, immune system dysfunction and pathology of
diﬀerent systems of the neurotransmitters in schizophrenia (Yao and
Keshavan, 2011). On the other hand, in addition to the dopami-
nergic_dysfunctions in schizophrenia, other systems of neurotransmitters
are engaged including GABA, serotonin, acetylcholine, noradrenalin (NA)
and glutamate. Glutathione system dysfunctions have been illustrated in
schizophrenia. Glutathione level, in these patients, decreases in blood,
cerebrospinal ﬂuid, and prefrontal cortex (Bloch, 2009; Marek and Behl,
2010). There is a 27% reduction in the cerebrospinal ﬂuid levels of GSH in
untreated patients with schizophrenia (Do et al., 2000) and 41% reduction
in the caudate postmortem of schizophrenic patients (Yao et al., 2006).
Previous studies recorded a signiﬁcant decrease in the blood levels of total
glutathione (Pavlovic et al., 2002 and Gawryluk, 2011) and signiﬁcant
decreased plasma levels of glutathione levels in drug-naive ﬁrst-episode
patients with schizophrenia (Raﬀa et al., 2011). In addition, the patho-
physiology of the negative symptoms associated with the cognitive defects
is still unknown (Dickinson and Harvey, 2009). Despite availability of
various antipsychotics, negative symptoms and cognitive impairment are
diﬃcult to treat. Antipsychotic monotherapy is not eﬀective in most of
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such patients and there have been still many health problems, especially in
the treatment of negative symptoms as well as cognitive dysfunctions.
Cognitive impairment represents a core feature of schizophrenia in the
majority of patients with the disorder (Lewis, 2004). Cognitive functions
have been shown to be associated with medication adherence and are the
strongest predictors of patients' ability to manage medications (Jeste et al.,
2003). The use of new pharmacological compounds on the treatment of
schizophrenia has been suggested (Harrison et al., 2001; Hamer and
Haddad, 2007). Furthermore alternative treatments, including anti-oxi-
dant therapy has been considered in the treatment of patients with schi-
zophrenia (Bondy and Spellmann, 2007; Reddy and Reddy, 2011;
Bitanihirwe and Woo, 2011). N-Acetyl cysteine (NAC), an acetylated de-
rivative of amino acid L-cysteine that is quickly absorbed orally, is a GSH
precursor with antioxidant, neurotropic and anti-inﬂammatory properties,
as well as modulatory eﬀects on dopaminergic and glutamatergic systems
(Arakawa and Ito, 2007). NAC acts eﬀectively in the regulation of dopa-
mine and glutamate neurotransmitter systems involved in schizophrenia
(Olive et al., 2012) leading to regulate the synthesis of cysteine, releasing
glutamate in the synaptic level and stimulating N-methyl-D-aspartate
(NMDA) receptor (Steullet et al., 2006; Gere-Paszti and Jakus, 2009).
There is increasing evidence that they converge on a common pathological
hub that involves NMDA receptor hypofunction and oxidative stress in
Schizophrenia (Hardingham and Kim, 2016(, GSH is depleted during
oxidative stress, which can be reversed with NAC treatment (Atkuri et al.,
2007).In vitro and in vivo studies have shown that NAC acts as cysteine
prodrug and GSH precursor (Zafarullah et al., 2003). Also, the antioxidant
role of NAC has been known in previous studies through_ regulating the
synthesis of glutathione which decreases in schizophrenia (Altuntas et al.,
2000: Gawryluk, 2011; Dodd et al., 2008). NAC has been eﬀective in re-
verse oxidative stress associated with_ mitochondrial dysfunction (Wang
et al., 2009; Otte et al., 2011).Another potential eﬀect of NAC is the anti-
inﬂammatory role that prevents the production of cytokines, leads to in-
crease of glutamate, and regulates oxidative stress (Csontos et al., 2012;
Tsai et al., 2009; Kigerl et al., 2012).
In a double-blind, randomized, placebo controlled trial on 140 pa-
tients with chronic schizophrenia, 69 patients treated with 2000 mg/
day, NAC during 6 months had signiﬁcant improvement in negative
symptoms (Berk et al., 2008). Another study showed that patients with
schizophrenia had signiﬁcant improvement in the social interactions,
motivations, psychomotor stability and behavior stability after treat-
ment with NAC (Berk et al., 2011). In a small study, 11 patients with
schizophrenia had signiﬁcant reduction in the potential of auditory
stimulation that was recorded by Mismatched negativity (MMN) after
8 weeks treatment with NAC. (Lavoie et al., 2008). A case report de-
monstrated signiﬁcant improvement in symptoms after 600 mg daily
dose of NAC for 4 weeks in a young woman with treatment-resistant
schizophrenia (Bulut et al., 2009). Finally in a randomized, double-
blind, placebo controlled study, 42 patients with chronic schizophrenia
received (2000 m g/day) NAC during 2 months; as a result, NAC-
treated patients showed signiﬁcantly greater improvement in the total
and negative symptoms (Farokhnia et al., 2013). All the above men-
tioned studies investigated the eﬀect of 2000 mg/day dose of NAC on
symptoms of schizophrenia. There has been no study to investigate the
eﬀect of other doses of NAC on symptoms of schizophrenia. Therefore,
we attempted to investigate the ability of the lower dose of NAC
(1200 mg daily) in increasing the eﬀect of anti-psychotic drugs on the




This study was conducted as a twelve week, double blind rando-
mized, placebo controlled, clinical trial. The study was performed on
outpatients referred to Rehabilitation center of Kargarnejad psychiatric
hospital in Kashan, aﬃliated with Kashan University of Medical
Sciences (KUMS) from July 2015 to July 2016. The project was ap-
proved by the research and Medical Ethics Committee of Kashan
University of Medical Sciences and carried out in agreement with de-
claration of Helsinki and its subsequent revisions. After complete ex-
planation of the study details, written informed consent was obtained
from the patients and legally authorized representatives in accordance
with the procedures deﬁned by the local Institutional Review Board.
The participants were informed that they were free to withdraw from
the study at any time. This trial was registered at the Iranian Clinical
Trials Registry (IRCT:2015080223463 N1 www.irct.ir)
2.2. Participant
Patients who met the diagnostic criteria for schizophrenia based on
the Diagnostic and Statistical Manual (DSM)-IV-TR diagnosed with
chronic schizophrenia and were recruited for this study.
Patients were male or female with aged 18 to 65 years. The diag-
nosis was established by means of chart review and semi-structured
clinical interview for DSM-IV-TR Axis I disorders (SCID). The patients
were included if they (1) met DSM-IV-TR criteria for schizophrenia, (2)
had minimum Positive and Negative Symptoms Scale (PANSS) score of
55 (3) had disease duration of at least 2 years (4) treat with chlorpro-
mazine equivalent to 300–1000 mg (except clozapine) and antic-
holinergic agents equivalent to 4–8 mg Trihexyphenidyl during the
6 months prior. One hundred patients were screened for the eligibility
criteria, 16 excluded before run in study and 84 patients were rando-
mized into 2 groups. Two patients from NAC group and three patients
from Placebo group dropped out from the trial because of either
withdrawal of consent. Fig. 1 shows ﬂow chart of study.
2.3. Exclusion criteria
Patients were excluded if they had any of the following criteria: (1)
additional axis I diagnosis according to the DSM-IV-TR, (2) other neu-
rologic or organic illnesses based on clinical examinations or laboratory
ﬁndings, (3) Intelligent Quotient (IQ) of< 70 (mental retardation)
based on clinical judgment, (4) any alcohol or substance dependence
(except nico tine or caﬀeine) within past 6 months of screening, (5)
score of≥14 on a 17-item Hamilton Depression Rating Scale (HDRS) or
a score of≥4 on depression item of PANSS since signiﬁcant depression
can cause misinterpretation of the negative symptom,(6) treatment
with clozapine, lithium, sodium valproic acid, carbamazepine, (7)
presence of liver, kidney, thyroid, hematologic diseases and any serious
chronic physical illness, (8) pregnancy or lactation, (9) patients who
have recently received the known glutathione reduction inhibitor (like
selenium or vitamin E), (10) the use of antidepressants including tri-
cyclic antidepressants, monoamine oxidase inhibitors, selective ser-
otonin reuptake inhibitors in recent months,(11) previous allergic re-
action to N-acetyl cysteine or any combination that includes the N-
acetyl cysteine, (12) the history of seizure s, stroke and traumatic brain
injury, (13) Suicidal ideation based on clinical judgment.
2.4. Interventions
After arriving the participants to the study, a number was assigned
to each person and the participants randomized into two groups by
Permuted Blocked Randomizations (each group n = 42).
All patients have been received antipsychotic (except clozapine)
equivalent 300 to 1000 mg chlorpromazine from 6 months ego. After
dividing participants were equally randomized into 2 groups, case
group received 600 mg, two times a day (1200 mg/day) NAC (Hexal
Pharmaceuticals, Holzkirchen, Germany) and placebo group received
placebo (Barij Essence, Kashan, Iran). There was not any changes in
dosages and type of prescribed therapy during study period.
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2.5. Outcomes
Severity of psychiatric symptoms was assessed with Positive and
Negative Symptoms Scale (PANSS), Neurocognitive function was eval-
uated via assessing changes in several domains of cognitive functioning.
The Mini-Mental State Examination (MMSE), the Digit Span Forward
and Backward Test, the Digit Symbol Substitution Test (DSST) and the
Stroop Color-Word Test were used to assess cognitive function. These
tests widely used in the study of cognition in schizophrenia. Patients
attended in ﬁve visits: initial screening and randomization (week−1),
and four further visits at the weeks of 0, 4, 8, 12. Data for clinical and
neurocognitive assessments were collected at weeks 0, 4, 8 and 12.
Measuring devices in this research was PANSS test made by Kay and
colleagues as a means of measurement. The PANSS is a 30-item rating
scale consisting of validated subscales to examine positive (7 items),
negative (7 items), and general psychopathological (16 items) symp-
toms of schizophrenia. These 3 subscales are summed up in the PANSS
total score (Kay et al., 1987). In Iran, the questionnaire was standar-
dized (Bakhshipour Roudsari and Dejkam, 2005) and the PANSS test
has been used in several clinical trials of schizophrenia in the Iranian
population (Rezaei et al., 2013; Nikbakhat et al., 2016).
The following cognitive tests were administered at baseline and
12 weeks.
Adverse Events and safety thorough physical examination and ECG
were performed at screening and each visit. All patients were en-
couraged to inform their health care providers and the research team
about any unexpected adverse events at any time during this project. In
order to provide more safety, open-ended questioning about any
probable side eﬀects were carried out during each visit followed by
completion of a systematic 25-item questionnaire checklist of a broad
range of alarming symptoms or complaints. Extra pyramidal side eﬀects
were also evaluated with physical examination at baseline and all post-
baseline visits. The behavior appraisal and adverse eﬀects checklist
were completed by independent raters. In case of facing any side eﬀect,
an expert psychiatrist was responsible for deciding whether the patient
was eligible to continue with the same drug dose, to continue with
reduced dose or to discontinue.
2.6. Randomization and blinding
Randomization assignment was done using computer-generated
random numbers and by a trained staﬀ at the clinic as blindness.
Allocation concealment was done using sequentially numbered, sealed,
opaque packages. Both randomization and allocation were carried out
by independent persons who were not involved elsewhere in the study.
Patients, nurses, and physicians responsible for referring the patients,
and the statistician, as well as the investigators who rated the patients
and administered the drugs, were all blinded to the allocation. Placebo
tablets were identical to NAC tablets in shape, odor, size, and color.
They were all kept in identical containers and were administered by an
investigational drug pharmacist.
2.7. Statistical analysis
IBM SPSS Statics version 20 (IBM Corporation) was used for data
analysis. Continuous variables are reported as mean (SD) and catego-
rical variables as number (percent). Mean diﬀerences (MD) are de-
scribed with 95% conﬁdence intervals [MD (95% CI)]. Independent
sample t-test was used in order to compare the mean score changes of
PANSS between the two groups at baseline and trial endpoint. ANOVA
with repeated measures was employed to evaluate the interaction of
time X treatment for PANSS scores between the two groups, assuming
the study groups (NAC vs. placebo) as the between-subject variable and
study measurements as the within-subject factor (time). In case of sig-
niﬁcant Mauchly's test of sphericity, Greenhouse-Geisser correction for




One hundred patients were screened for the eligibility criteria and
84 patients were randomized into 2 groups. Two patients from NAC
group and three patients from Placebo group dropped out from the trial
84 randomized
Assessed for eligibility n:100 Fig. 1. Flow diagram of the trial.
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because of either withdrawal of consent. A total number of 79 patients
(placebo, 39; NAC, 40) completed the trial (Fig. 1).
To get assurance about patient compliances for administered drugs
interviewed with family members of patients. Respect to it, all patients
used prescribed drugs according with psychiatric orders. Demographic
characteristics of both groups were compared through t-test, Chi square
and Fisher's Exact Test methods. There was not signiﬁcant diﬀerence
(P = 0.05), except for residential place variable. The mean age was
39.41 ± 13.95 and 38.75 ± 12.50 for treatment and placebo group
respectively. Other details are presented in Table 2. (See Table 1.)
The baseline score of PANSS subscales were compared between two
groups, using t-test analysis. The results are presented in Table 3. As it is
shown there were signiﬁcant diﬀerences between two groups. There-
fore it was required to adjust baseline score across follow up period
times.
3.2. Outcomes
To get insight about the eﬀect of drug across measurement times
and adjust of baseline score of PANSS diﬀerences, the repeated measure
analysis was applied, whilst adjusting the residential places the cov-
ariate variable.
After checking repeated measure prerequisite assumptions with
Mauchly and box test the PANSS subscale scores were compared within
and between study groups across measurement times (at the baseline,
4th, 8th and 12th weeks).
3.3. The PANSS positive subscale
Respect to repeated measure analysis results with applying
Greenhouse-Geisser correction, there was not within groups signiﬁcant
diﬀerence over time (F = 1.2, df = 2.25, P = 0.31), however there was
between groups signiﬁcant diﬀerences (F = 5.47, df = 1, P = 0.02). In
addition, there was interaction eﬀect between time and group variables
(F = 3.30, df = 2.25, P = 0.02). In other words, the reduction of
PANSS positive score for NAC group was signiﬁcantly greater than
placebo group.
3.4. The PANSS negative subscale
For negative PANSS score with applying Huynh-Feldt correction,
the PANSS negative score within study groups changed over time,
signiﬁcantly(F = 10.49, df = 2.56, P < 0.001). In between group
comparison there was signiﬁcant diﬀerence between NAC and placebo
groups (F = 0.20, df = 1, P = 0.65).There was interaction between
group and time (F = 27.79, df = 2.56, P < 0.001). The negative
PANSS score in NAC group reduced gradually whilst for placebo group
it was increased.
3.5. The PANSS general psychopathology subscale
With applying Huynh-Feldt correction, the general symptoms did
not change over time (F = 4.52, df = 2.34, P < 0.01).
The mean general symptoms score of PANSS signiﬁcantly decreased
in the NAC group (P < 0.001) whilst for placebo group it was
Table 1
Summary of neuropsychological tests.
Cognitive tests Description References
Digit Symbol Substitution Test (DSST) from the Wechsler Adult
Intelligence Scale-Revised (WAIS-R)
A test assesses attention and speed of Processing. It consists of digit-symbol pairs
followed by a list of digits. Each numeral (1 through 9) is associated with a diﬀerent
simple symbol. Subjects are required to copy as many of the symbols associated with
the numerals as possible in 90 s. The number of correct symbols within the allowed
time is measured.
Wechsler, 1981
Sumiyoshi et al., 2003
Digit span test from the Wechsler Adult Intelligence Scale-
Revised (WAIS-R)
A test assesses short-term and working memory. Two digit sequences of the same
length are presented at each stage.
Turner et al., 2003
Wechsler, 1981
Stroop Color and Word Test (SCWT) A test to assess the ability to inhibit cognitive interference that occurs when the
processing of a speciﬁc stimulus feature impedes the simultaneous processing of a
second stimulus attribute, well-known as the Stroop Eﬀect. In the Color Task, the
individual reads aloud a list of color names in which no name is printed in its
matching color. In the Color-Word Task, the individual names the ink color in which
the color names are printed.
Trenerry et al., 1989
Scarpina and Tagini,
2017
Mini-Mental State Examination–(MMSE) MMSE is a tool that can be used to assess mental status. It assesses orientation,
registration, attention and calculation, recall, and language. The maximum score is
30. A score below 25 suggests possible impairment.
Crum et al., 1993
Seyedian et al., 2008
Table 2
Demographic characteristics of study participants.
Variable Study group P-value
NAC Placebo
Age (mean; SD) 38.7 (1.9) 39.4 (2.2) n. sa
Duration of illness
(mean; SD)
13.8 (9.9) 17(11.6) n. s
Type of antipsychotic
drug
Typical 10 (25.0) 13 (33.3) n. s
Atypical 27 (67.5) 23 (59.0)
Typical
+ Atypical
3 (7.5) 3 (7.7)
Gender (%) Male 18 (45) 20 (51.3) n. s
Female 22 (55) 19(48.7(
Residential place (%) Urban 26 (65) 17 (43.6) P < 0.05
Rural 14 (35) 22 (56.4)
Education (%) Illiterate 3 (7.5) 7 (17.9) n. s
Elementary 15 (37.5) 18 (46.2)
Intermediate 8 (20.0) 10 (25.6)
Diploma 9 (22.5) 2(5.1)
High educated 5)12.5) 2(5.2)
Job (%) Household 16 (40.0) 10 (25.6) n. s
Unemployed 20 (50.0) 26(66.7)
Employed 2 (5.0) 1(2.6)
Others 2 (5.0) 2 (5.1)
Marital status (%) Single 19 (47.5) 14 (35.9) n. s
Married 10 (25.0) 15 (38.5)
Widow/divorced 11 (27.5) 10 (25.7)
a n. s; Non signiﬁcant.
Table 3
Baseline PANSS score.
PANSS subscales Study group P-value
NAC (SD) Placebo (SD)
Positive 22.9 (10.8) 17.7 (5.8) P < 0.01
Negative 30.4 (7.3) 26.5 (6.2) P < 0.05
General 50.5 (14.0) 43.5 (10.6) P < 0.05
Total 104.0 (27.0) 87.7 (17.4) P < 0.01
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increased (P = 0.031). Compared to placebo group the eﬀect of NAC on
general symptoms improved over times. It means interaction between
time and administered drug (F = 24.59, df = 2.34, P < 0.001).
3.6. The PANSS total subscale
For total PANSS score, the score changed over time, signiﬁcantly
(F = 9.10, df = 2.54, P < 0.001). The changes of the PANSS total
score over times for study groups were diﬀerent (F = 31.57, df = 2.54,
P < 0.001). The total PANSS score of NAC group declined over times
whilst it was increased for placebo group.
Graph 1 shows trend of changes of PANSS scores respect to study
group.
3.7. Cognitive functioning assessment
Table 4 summarizes the results of the tests of cognitive functioning
for both groups.
The mean MMSE score increased from 23.1 ± 4.4 at base line to
25.55 ± 15.4 at week 12 in the NAC group and from 23.79 ± 3.8 at
baseline to 24.15 ± 3.76 at week 12 in the placebo group. However,
these increases were signiﬁcantly diﬀerent at the end of study period
(P < 0/001).
The mean Digit Span test (Forward) score increased from 6.2 ± 2.8
at base line to 7.9 ± 3.38 at week 12 in the NAC group and decreased
from 5.76 ± 2.6 at baseline to 5.66 ± 2.59 at week 12 in the placebo
group. However, there was signiﬁcant diﬀerence between both groups
(P < 0/001).
The mean Digit Span test (backward) score increased from
3.47 ± 1.8 at base line to 5.35 ± 2.79 at week 12 in the NAC group
and decreased from 3.28 ± 1.65 at baseline to 3.23 ± 1.54 at week
12 in the placebo group. However, the diﬀerence between both groups
remained signiﬁcant (P < 0/001).
The mean Digit Symbol Substitution Test score increased from
Graph 1. The subscales changes of PANSS score within and between study groups during follow-up.
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17.37 ± 9.8 at base line to 25.07 ± 11.9 at week 12 in the NAC
group and decreased from 27.92 ± 14.84 at baseline to
27.84 ± 15.15 at week 12 in the placebo group. Although, there was
signiﬁcant diﬀerence between both groups (P = 0/003).
The mean stroop test (letter) score decreased from 37.32 ± 4.8 at
base line to 35.07 ± 5.45 at week 12 in the NAC group and increased
from 37.74 ± 5.25 at baseline to 38.53 ± 3.5 at week 12 in the
placebo group. Even so, the diﬀerence between both groups stayed
signiﬁcant (P < 0/001).The mean stroop test (color) score decreased
from 31.79 ± 3.83 at base line to 29.55 ± 5.08 at week 12 in the
NAC group and increased from 32.10 ± 4.38 at baseline to
32.74 ± 4.19at week 12 in the placebo group. However, these in-
creases were signiﬁcantly diﬀerent at the end of study period (P < 0/
001).
3.8. Adverse eﬀects and safety
There were neither signiﬁcant eﬀects of 1200 mg NAC on safety
parameters, no reported adverse events by the participants. Only one
patient in NAC group reported the mild abdominal cramp and dis-
comfort, this adverse eﬀect, did not result in discontinuation of the drug
intake.
4. Discussion
In this study, we found signiﬁcant reduction in the mean negative
symptoms score, the positive symptom score, the general psycho-
pathology score and total score for the NAC group compared with the
placebo group by the study endpoint. We also found a signiﬁcant
time × treatment interaction for all PANSS scores.
The reduction of PANSS positive score for NAC group was sig-
niﬁcantly greater than placebo group. In a similar study by Berk et al.
conducted on 140 patients with chronic schizophrenia in 2008, 84
patients were treated by with 2000 mg per day NAC for 6 months, as
adjuvant therapy of antipsychotics and no signiﬁcant changes in scale
of PANSS test positive symptoms were seen (Berk et al., 2008). In an-
other double-blind study performed in 2013 by Farokhnia et al. in Iran
on 42 patients with chronic schizophrenia, the eﬀect of the adjuvant
therapy of NAC (2000 mg daily) to Risperidone (at least 6 mg per day)
for 8 weeks on symptoms of schizophrenia were evaluated. They did not
observed any signiﬁcant eﬀects of the drugs on the positive symptoms
(Farokhnia et al., 2013). Therefore, the diﬀerences between the results
of these studies on the improvement of positive symptoms with NAC
therapy can be attributed to diﬀerences in studied populations or study
designs or diﬀerences of doses. That warrant further investigation to be
clariﬁed. To date, any clinical trials have not investigated this dose of
NAC on positive symptoms in patients with schizophrenia.
Also, for negative PANSS score there was signiﬁcant diﬀerence
between the two groups and the administered drug eﬀects on negative
PANSS score changed signiﬁcantly over time. The results of this study
are similar to the results of the study performed by Berk et al. in 2008
(Berk et al., 2008) and Farokhnia et al. in 2013 (Farokhnia et al., 2013).
Therefore, this study showed that lower doses (1200 mg) of NAC have
been prescribed compared to other studies with higher dose (2000 mg
daily) is eﬀective on negative symptom of schizophrenia. This dose is
safer and cost-beneﬁt.
About general symptoms there was signiﬁcant diﬀerence between
the study groups. The PANSS mean score of the general symptoms
signiﬁcantly decreased among the patients studied in the NAC group.
Whilst, the PANSS mean score of the general symptoms signiﬁcantly
increased among the patients studied in the placebo group. The results
of this study were similar to the results of the study performed by Berk
et al. in 2008 (Berk et al., 2008) in which the general symptoms of the
schizophrenic patients in the NAC group had signiﬁcant improvement
compared to the placebo group (Berk et al., 2008) but our results were
opposite of the study of Farokhnia et al. in 2013 (Farokhnia et al., 2013)
in which was not determined any signiﬁcant diﬀerence in the reduction
of PANSS general psychopathology subscale scores. Therefore, the dif-
ferences between the results of the 2 studies on the improvement of
general symptoms with NAC therapy can be attributed to diﬀerent
doses of the drug, the methodology the study population, the study
design or more sample size in our study and longer observational period
in our study (12 weeks comparison with 8 weeks) that warrant further
investigation to be clariﬁed.
Also, for total PANSS score there were signiﬁcant diﬀerence be-
tween study and placebo group. The mean score of the patients studied
in the group receiving NAC has been signiﬁcantly decreased. While, the
score mean of the total symptoms PANSS of the patients in the group
receiving the placebo has been increased at the end of the study. The
results of this study are similar to the results of the study performed by
Berk et al. in 2008 (Berk et al., 2008) and Farokhnia et al. in 2013
(Farokhnia et al., 2013) on the total symptoms of the patients
(Farokhnia et al., 2013). Therefore, this study showed that lower doses
(1200 mg) of NAC have been prescribed compared to other studies with
higher dose (2000 mg daily) is eﬀective on total symptom of schizo-
phrenia too. This dose is safer and cost-beneﬁt.
In the present study, NAC enhanced speed of processing and at-
tention on the DSST, whilst in the patients given placebo at 3 months,
slight deterioration was noted in the speed of processing. In a double-
blind, randomized, placebo-controlled trial in 63 schizophrenic pa-
tients, they assessed the eﬀect of NAC supplementation (2700 mg/day,
6 months) on PANSS, neurocognition, and redox markers (brain GSH,
blood cells GSH levels, GSH peroxidase activity). No changes in nega-
tive or positive symptoms or functional outcome were observed with
NAC, but signiﬁcant improvements were found in favor of NAC on
neurocognition (processing speed). NAC improved the processing speed
Table 4
The eﬀects of NAC compared with placebo on measures of cognitive functioning over the 12-week study period.
Cognitive assessment NAC (N = 40)
Mean ± SD
Placebo (N = 39)
Mean ± SD
Baseline 12 weeks Baseline 12 weeks P-value
MMSE* 23.1 ± 4.4 25.55 ± 15.4 23.79 ± 3.8 24.15 ± 3.76 < 0/001
Digit Span test
Forward 6.2 ± 2.8 7.9 ± 3.38 5.76 ± 2.6 5.66 ± 2.59 < 0/001
Backward 3.47 ± 1.8 5.35 ± 2.79 3.28 ± 1.65 3.23 ± 1.54 < 0/001
DSST 17.37 ± 9.8 25.07 ± 11.9 27.92 ± 14.84 27.84 ± 15.15 0/003
Stroop test (Letter)
37.32 ± 4.8 35.07 ± 5.45 37.74 ± 5.25 38.53 ± 3.5 < 0/001
Stroop test (Color) 31.79 ± 3.83 29.55 ± 5.08 32.10 ± 4.38 32.74 ± 4.19 < 0/001
Data were analyzed using repeated-measures analysis of variance (ANOVA). P-value was calculated from time by group interaction. MMSE: Mini Mental State Examination, SD: standard
deviation, DSST: Digit Symbol Substitution Test.
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(PS) factor containing these tasks (Conus et al., 2017). A study by Keefe
et al. in 2006, they reported the neurocognitive data from patients who
participated in the CATIE (Clinical Antipsychotic Trials of Intervention
Eﬀectiveness) Schizophrenia trial. By analyzing data from a compre-
hensive test battery, authors have found that the DSST by itself ac-
counted for the most of the test variance (Keefe et al., 2006). Perfor-
mance on the DSST represents attention and processing speed. This
neurocognitive impairment has been found to be correlate with a
variety of clinically important features of schizophrenia, such as daily
life activities, job tenure, and independent living status (Sadock and
Sadock, 2007). Therefore this study indicated that adjunctive N-acetyl
cysteine therapy has beneﬁcial eﬀects on speed of processing and at-
tention. There is ample evidence to suggest that increased levels of
oxidative stress, inﬂammation, mitochondrial dysfunction and apop-
tosis are associated with clinically meaningful cognitive deterioration
(Skvarc et al., 2017). NAC can be protects against oxidative stress and is
likely neuroprotective demonstrating pre-clinical eﬃcacy in reducing
markers of oxidative stress and the severity of cognitive dysfunction in
animal models (Hsiao et al., 2012; Huang et al., 2010). Similar oxida-
tive responses have been detected in humans (Moreira et al., 2007).
Supplementation of NAC can be eﬀective in reducing the severity of
cognitive changes associated with a variety of disorders characterized
by oxidative stress (Skvarc et al., 2017).
Signiﬁcant improvements were observed in performance on short-
term and working memory, as measured by the digit span test. In ad-
dition, NAC signiﬁcantly improved attention and executive functioning
on the stroop test. Finally signiﬁcant improvements in the mean MMSE
score were observed. In study of Rapado-Castro et al. in 2016, 58
participants with Psychotic disorders (both aﬀective and non-aﬀective
disorders) received 2 g/day of NAC for 24 weeks. Attention, working
memory and executive function domains were assessed. They reported
NAC results in a signiﬁcant improvement only in working memory in
the NAC-treated group (Rapado-Castro et al., 2017). The diﬀerences
between the results of the 2 studies on the improvement of attention
and executive function with NAC therapy in our study can be attributed
to diﬀerences in studied population, all of participants in our study
were patients with diagnosis of schizophrenia but in study of Rapado-
Castro et al., patients with Psychotic disorders (both aﬀective and non-
aﬀective disorders), were included. That warrants further investigations
to be clariﬁed. Other study that evaluated the eﬀect of NAC on
symptom of schizophrenia, did not investigated the eﬀect of NAC on
cognitive impairment (Berk et al., 2008; Farokhnia et al., 2013; Lavoie
et al., 2008 and Bulut et al., 2009). Therefore we had no prior data to
calculate base power.
N-Acetyl cysteine appears to be promising in the treatment of
schizophrenia. There are several reasons to explain why NAC can be
helpful in treating schizophrenia. N-Acetyl cysteine (NAC) is derived
from the amino acid L-cysteine (Arakawa and Ito, 2007). When NAC
reaches brain glial cells, it is oxidized to cysteine, then enters the cells
in exchange for glutamate and leads to increase extracellular glutamate.
NAC acts eﬀectively in the regulation of dopamine and glutamate
neurotransmitter systems involved in schizophrenia (Olive et al., 2012)
leading to regulate the synthesis of cysteine, releasing glutamate in the
synaptic level and stimulating N-methyl-D-aspartate (NMDA) receptor
(Steullet et al., 2006; Gere-Paszti and Jakus, 2009). Also, the anti-
oxidant role of NAC has been known in previous studies through reg-
ulating the synthesis of glutathione which decrease in schizophrenia
(Altuntas et al., 2000; Gawryluk, 2011; Dodd et al., 2008). On the other
hand, NAC has been eﬀective in reverse oxidative stress associated with
mitochondrial dysfunction (Wang et al., 2009; Otte et al., 2011). An-
other potential eﬀect of NAC is the anti-inﬂammatory eﬀect that pre-
vents the production of cytokines, leading to increase glutamate and
regulates oxidative stress (Csontos et al., 2012; Tsai et al., 2009; Kigerl
et al., 2012). Glutamatergic receptors are among the most promising
biological targets for cognitive-enhancing drugs in schizophrenia.
This trial showed that, 1200 mg of NAC is safer. To date, no clinical
trial has investigated this dose of NAC on symptoms in patients with
schizophrenia. Only one patient in NAC group reported the mild ab-
dominal cramp and discomfort. This adverse eﬀect did not result in
discontinuation of the drug intake. Other study performed by Berk et al.
in 2008 (Berk et al., 2008) and Farokhnia et al. in 2013 (Farokhnia
et al., 2013) prescribed higher dose (2000 mg daily) of NAC, In clinical
trial of Farokhnia et al. in 2013 (Farokhnia et al., 2013), some adverse
eﬀects such as drowsiness, constipation, dizziness, vomiting, increased
appetite, nausea, headache, dry mouth were observed over the course
of the trial on the basis of the adverse eﬀects checklist. But we don't
detected signiﬁcant diﬀerence between the 2 groups in the frequency of
adverse eﬀect so it seems the dose of 1200 mg NAC is more safe and
cost-beneﬁt than 2000 mg/day NAC.
So, the results of this study support the eﬀectiveness of oral NAC,
1200 mg daily, in reduction of the score of PANSS in the patients with
chronic schizophrenia. Of course, improvement happened in negative,
general and total symptoms and regarding cognitive functions, it was
also observed in some explored areas, such as attention, short-term and
working memory, executive functioning and speed of processing. The
cognitive impairment and negative symptoms represent a cardinal
feature of schizophrenia and are strong predictors of poor vocational
and social outcomes. Our ﬁndings indicate that adjunctive N-acetyl
cysteine therapy has beneﬁcial eﬀects on cognitive functioning or
psychopathology among patients with schizophrenia.
The results of this trial include several limitations. Firstly, we tested
only one dose of NAC.
Secondary, we could not evaluate a biomarker of glutathione status
to gauge the biological eﬀects of the NAC dose. Thirdly, this study had a
relatively short duration of intervention. Finally, cognitive impairment
evaluate only in some area of cognitive functioning. Despite these
limitations, we found evidence of signiﬁcant beneﬁt. This trial may now
be utilized for future studies. Additional studies with long-term follow-
up periods and other dose of NAC seem to be essential to reinforce
clinical use of adjuvant NAC in patients with schizophrenia. In addition,
further studies that address the limitations described above is needed to
conﬁrm NAC eﬀect on a wider range of area of cognitive functioning in
schizophrenia.
5. Conclusion
The present study detected improvement in negative, general and
total psychopathology symptoms as well as cognitive performance with
NAC treatment. It is also well-tolerated, safe and easy-to-use agent as an
eﬀective therapeutic strategy to improve outcome in schizophrenia
treatment.
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